Laboratoire d'Innovation Therapeutique, "Stem cell, Organogenesis and Regenerative Medicine" Master Program, Lebanese University, Faculty of Sciences, Beirut, Lebanon.
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Curr Mol Med. 2021;21(6):441-456. doi: 10.2174/1566524020999201117120147.
Severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2) is an extremely pathogenic virus belonging to the family of Coronaviridae. First identified in Wuhan, China in December 2019 after an epidemiological investigation of an emerging cluster of pneumonia of unknown etiology, SARS-CoV-2 was declared the cause of a pandemic on March 11 by the World Health Organization (WHO), pointing to the over 118000 cases of Coronavirus disease 2019 (COVID-19) in over 110 countries. Despite the promising results of drug repositioning studies in the treatment of COVID-19, the evidence of their safety and efficacy remains inconclusive. Cell based therapy has been proven safe and possibly effective in treating multiple lung injuries and diseases, but its potential use in the treatment of COVID-19 has not been yet elucidated. Our aim in this review is to provide an overview of the immunomodulatory effect and the regenerative capacity of stem cells and their secretome in the treatment of many diseases including lung injuries. Those findings may contribute to a better understanding of the potential of stem cell therapy in SARS-CoV-2 infection and its potential use in order to find a solution for this healthcare crisis.
严重急性呼吸综合征相关冠状病毒 2(SARS-CoV-2)是一种极其致病的病毒,属于冠状病毒科。该病毒于 2019 年 12 月在中国武汉,在对不明病因的新发肺炎聚集性病例进行流行病学调查后首次被发现。世界卫生组织(WHO)于 2020 年 3 月 11 日宣布,SARS-CoV-2 是导致大流行的原因,并指出在 110 多个国家有超过 118000 例 2019 年冠状病毒病(COVID-19)病例。尽管在 COVID-19 治疗中药物重新定位研究取得了可喜的结果,但它们的安全性和疗效证据仍不确定。基于细胞的治疗已被证明在治疗多种肺损伤和疾病方面是安全且可能有效的,但尚未阐明其在 COVID-19 治疗中的潜在用途。我们在这篇综述中的目的是提供干细胞及其分泌组在治疗多种疾病包括肺损伤中的免疫调节作用和再生能力的概述。这些发现可能有助于更好地了解干细胞治疗在 SARS-CoV-2 感染中的潜力及其潜在用途,以找到解决这一医疗保健危机的方法。